The news is directly related to Phibro Animal Health. Morgan Stanley's reiteration of an Equal-Weight rating indicates that they believe the company's stock is fairly valued. The maintained price target of $18 also suggests that they do not expect significant price movement in the short term. Therefore, the impact on the stock price is likely to be neutral.